Proinsulin C-peptide human
Need Assistance?
  • US & Canada:
    +
  • UK: +

Proinsulin C-peptide human

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

It is a peptide consisting of 31 amino acids that connects the A and B chains of proinsulin, ensuring that its correct folding, is biologically active and regulates cellular function.

Category
Others
Catalog number
BAT-010604
CAS number
33017-11-7
Molecular Formula
C129H211N35O48
Molecular Weight
3020.26
Proinsulin C-peptide human
IUPAC Name
(4S)-4-amino-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[[2-[(2S)-2-[[2-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(1S)-4-amino-1-carboxy-4-oxobutyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
Synonyms
Insulin Precursor (57-87) (human); C-Peptide, Proinsulin; Human proinsulin C-peptide; H-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-OH; L-alpha-glutamyl-L-alanyl-L-alpha-glutamyl-L-alpha-aspartyl-L-leucyl-L-glutaminyl-L-valyl-glycyl-L-glutaminyl-L-valyl-L-alpha-glutamyl-L-leucyl-glycyl-glycyl-glycyl-L-prolyl-glycyl-L-alanyl-glycyl-L-seryl-L-leucyl-L-glutaminyl-L-prolyl-L-leucyl-L-alanyl-L-leucyl-L-alpha-glutamyl-glycyl-L-seryl-L-leucyl-L-glutamine
Appearance
White or Off-white Lyophilized Powder
Purity
95%
Density
1.328±0.06 g/cm3 (Predicted)
Boiling Point
2864.4±65.0°C (Predicted)
Sequence
EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ
Storage
Store at -20°C
Solubility
Soluble in Acetic Acid (1 mg/mL)
InChI
InChI=1S/C129H211N35O48/c1-58(2)42-77(155-113(195)74(31-39-102(184)185)151-127(209)105(65(15)16)162-114(196)71(25-32-88(131)167)145-95(174)54-141-126(208)104(64(13)14)161-115(197)72(26-33-89(132)168)150-118(200)80(45-61(7)8)156-121(203)83(48-103(186)187)159-112(194)73(30-38-101(182)183)148-107(189)67(18)143-109(191)69(130)24-36-99(178)179)111(193)138-50-93(172)135-49-92(171)136-55-98(177)163-40-20-22-86(163)124(206)140-51-94(173)142-66(17)106(188)137-52-96(175)146-84(56-165)122(204)157-81(46-62(9)10)119(201)152-75(27-34-90(133)169)128(210)164-41-21-23-87(164)125(207)160-78(43-59(3)4)116(198)144-68(19)108(190)154-79(44-60(5)6)117(199)149-70(29-37-100(180)181)110(192)139-53-97(176)147-85(57-166)123(205)158-82(47-63(11)12)120(202)153-76(129(211)212)28-35-91(134)170/h58-87,104-105,165-166H,20-57,130H2,1-19H3,(H2,131,167)(H2,132,168)(H2,133,169)(H2,134,170)(H,135,172)(H,136,171)(H,137,188)(H,138,193)(H,139,192)(H,140,206)(H,141,208)(H,142,173)(H,143,191)(H,144,198)(H,145,174)(H,146,175)(H,147,176)(H,148,189)(H,149,199)(H,150,200)(H,151,209)(H,152,201)(H,153,202)(H,154,190)(H,155,195)(H,156,203)(H,157,204)(H,158,205)(H,159,194)(H,160,207)(H,161,197)(H,162,196)(H,178,179)(H,180,181)(H,182,183)(H,184,185)(H,186,187)(H,211,212)/t66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,104-,105-/m0/s1
InChI Key
VOUAQYXWVJDEQY-QENPJCQMSA-N
Canonical SMILES
CC(C)CC(C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)O)NC(=O)C1CCCN1C(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)CNC(=O)C(C)NC(=O)CNC(=O)C2CCCN2C(=O)CNC(=O)CNC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CCC(=O)O)N
1.Sfrp5 associates with beta-cell function in humans.
Carstensen-Kirberg M1,2, Hatziagelaki E3, Tsiavou A3, Chounta A4, Nowotny P1,2, Pacini G5, Dimitriadis G3, Roden M1,2,6, Herder C1,2. Eur J Clin Invest. 2016 Mar 28. doi: 10.1111/eci.12629. [Epub ahead of print]
BACKGROUND: Secreted frizzled-related protein (Sfrp)5 improves insulin sensitivity, but impairs beta-cell function in rodents. However, the relationship between Sfrp5, insulin sensitivity and secretion in humans is currently unclear. Therefore, the aim of the study was to characterize the associations between serum Sfrp5 and indices of insulin sensitivity and beta-cell function from dynamic measurements using oral glucose tolerance tests (OGTT).
2.Cholecystokinin-Induced Gallbladder Emptying and Single-Dose Metformin Elicit Additive Glucagon-Like Peptide-1 Responses.
Rohde U1,2, Sonne DP1, Christensen M1,3, Hansen M1,2, Brønden A1, Toräng S2, Rehfeld JF4, Holst JJ2, Vilsbøll T1, Knop FK1,2. J Clin Endocrinol Metab. 2016 Mar 22:jc20161133. [Epub ahead of print]
CONTEXT: Bile acids have been suggested to mediate glucagon-like peptide-1 (GLP-1) secretion via activation of the bile acid receptor TGR5 on enteroendocrine L cells. Metformin too has been shown to increase GLP-1 levels. The effect of gallbladder emptying, metformin or a combination has however never been studied.
3.Trans-11 vaccenic acid improves insulin secretion in models of type 2 diabetes in vivo and in vitro.
Wang X1, Gupta J1, Kerslake M1, Rayat G2, Proctor SD1, Chan CB1,3. Mol Nutr Food Res. 2016 Apr;60(4):846-57. doi: 10.1002/mnfr.201500783. Epub 2016 Jan 20.
SCOPE: Trans-11 vaccenic acid (VA) is a fatty acid produced by ruminants entering the human food supply through meat and dairy products, which appears not to have the health risks associated with industrially produced trans-fatty acids. In this study, we investigated the effect of VA on insulin secretion in vivo in rats and in vitro in human and rat islets after diabetogenic insult.
4.A Nested Case-Control Study of Metabolically Defined Body Size Phenotypes and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC).
Murphy N1, Cross AJ1, Abubakar M2, Jenab M3, Aleksandrova K4, Boutron-Ruault MC5,6,7, Dossus L5,6,7, Racine A5,6,7, Kühn T8, Katzke VA8, Tjønneland A9, Petersen KE9, Overvad K10, Quirós JR11, Jakszyn P12, Molina-Montes E13,14, Dorronsoro M15, Huerta JM14, PLoS Med. 2016 Apr 5;13(4):e1001988. doi: 10.1371/journal.pmed.1001988. eCollection 2016.
BACKGROUND: Obesity is positively associated with colorectal cancer. Recently, body size subtypes categorised by the prevalence of hyperinsulinaemia have been defined, and metabolically healthy overweight/obese individuals (without hyperinsulinaemia) have been suggested to be at lower risk of cardiovascular disease than their metabolically unhealthy (hyperinsulinaemic) overweight/obese counterparts. Whether similarly variable relationships exist for metabolically defined body size phenotypes and colorectal cancer risk is unknown.
Online Inquiry
Verification code
Inquiry Basket